Amylyx Pharmaceuticals vs Septerna
AMLX and SEPN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMLX and SEPN compare
Amylyx Pharmaceuticals is the larger company, worth 1.6 times as much as Septerna ($3.1B against $1.9B).
Septerna scores higher on the StockData Score (8 against 6 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMLX | SEPN |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $1.9B |
| Share price | $27.52 | $40.02 |
| Change, 1 year | 117% | 72.0% |
| Change, 5 years | 168% | – |
| Beta (5Y) | 0.54 | 0.70 |
| Employees | 136 | 130 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 19.4× |
| P/B | 12.8× | 4.4× (better) |
| FCF yield | – | −4.2% |
| Fair value | – | $15.08 |
| Margin of safety | – | −165% |
| Growth | ||
| Revenue growth (TTM) | – | 337% |
| Profitability | ||
| Operating margin | – | −76.2% |
| Net margin | – | −61.3% |
| FCF margin | – | −80.6% |
| Return on equity | −74.7% | −14.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 12.12 (better) | 4.84 |
| Altman Z-score | 67.06 (better) | 5.91 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 102% |
| Held by insiders | 7.8% | 27.9% |
| Insider net buying, 12 months | −$17.2M (better) | −$80.9M |
| Short interest, % of float | 12.5% | 10.0% |
Go deeper
- AMLX stock overview
- AMLX income statement
- AMLX valuation and score
- SEPN stock overview
- SEPN income statement
- SEPN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.